ATE249460T1 - 1,4-diazabicyclo(3.2.2)nonanderivate, deren herstellung und deren verwendung in heilkunde - Google Patents

1,4-diazabicyclo(3.2.2)nonanderivate, deren herstellung und deren verwendung in heilkunde

Info

Publication number
ATE249460T1
ATE249460T1 AT99973291T AT99973291T ATE249460T1 AT E249460 T1 ATE249460 T1 AT E249460T1 AT 99973291 T AT99973291 T AT 99973291T AT 99973291 T AT99973291 T AT 99973291T AT E249460 T1 ATE249460 T1 AT E249460T1
Authority
AT
Austria
Prior art keywords
nonander
diazabicyclo
medicine
derivatives
production
Prior art date
Application number
AT99973291T
Other languages
English (en)
Inventor
Alistair Lochead
Samir Jegham
Alain Nedelec
Frederic Galli
Jean Jeunesse
Luc Even
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of ATE249460T1 publication Critical patent/ATE249460T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT99973291T 1998-12-04 1999-12-01 1,4-diazabicyclo(3.2.2)nonanderivate, deren herstellung und deren verwendung in heilkunde ATE249460T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9815326A FR2786770B1 (fr) 1998-12-04 1998-12-04 Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique
PCT/FR1999/002975 WO2000034279A1 (fr) 1998-12-04 1999-12-01 Derives de 1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
ATE249460T1 true ATE249460T1 (de) 2003-09-15

Family

ID=9533582

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99973291T ATE249460T1 (de) 1998-12-04 1999-12-01 1,4-diazabicyclo(3.2.2)nonanderivate, deren herstellung und deren verwendung in heilkunde

Country Status (9)

Country Link
US (1) US6407095B1 (de)
EP (1) EP1135389B1 (de)
JP (1) JP4576052B2 (de)
AR (1) AR021534A1 (de)
AT (1) ATE249460T1 (de)
AU (1) AU1393000A (de)
DE (1) DE69911241T2 (de)
FR (1) FR2786770B1 (de)
WO (1) WO2000034279A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804430B1 (fr) * 2000-01-28 2002-03-22 Sanofi Synthelabo Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
FR2809730B1 (fr) * 2000-05-31 2002-07-19 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.2] nonanebenzoxazole, -benzothiazole et -benzimidazole, leur preparation et leur application therapeutique
FR2809731B1 (fr) 2000-05-31 2002-07-19 Sanofi Synthelabo Derives de 1,4-diazabicyclo-[3.2.2] nonane-pheylisoxazole, leur preparation et leur application en therapeutique
FR2809732B1 (fr) * 2000-05-31 2002-07-19 Sanofi Synthelabo DERIVES DE 4(-2-PHENYLTHIAZOL-5-yl)-1,4-DIAZABICYCLO-[3.2.2] NONANE, LEUR PREPARATION ET LEUR APPLICATION ENTHERAPEUTIQUE
US20020086871A1 (en) * 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
ES2275808T3 (es) * 2001-02-06 2007-06-16 Pfizer Products Inc. Composiciones farmaceuticas para el tratamiento de trastornos del snc y otros trastornos.
FR2832714B1 (fr) * 2001-11-23 2004-07-16 Sanofi Synthelabo Derives de 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
FR2832712B1 (fr) * 2001-11-23 2004-02-13 Sanofi Synthelabo Derives de 4-(oxadiazol-3-yl)-1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique
FR2832713B1 (fr) * 2001-11-23 2004-02-13 Sanofi Synthelabo Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
FR2834511B1 (fr) * 2002-01-07 2004-02-13 Sanofi Synthelabo Derives de 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, leur preparation et leur application en therapeutique
AU2003217747A1 (en) * 2002-02-26 2003-09-09 North Shore-Long Island Jewish Research Insitute Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
WO2004024729A1 (en) * 2002-09-10 2004-03-25 Pfizer Products Inc. Diazabicyclic compounds useful in the treatment of cns and other disorders
ATE353899T1 (de) 2002-09-30 2007-03-15 Neurosearch As Neue 1,4-diazabicycloalkanderivate, deren herstellung und verwendung
PT1551835E (pt) * 2002-09-30 2007-03-30 Neurosearch As Novos derivados de 1, 4-diazabicicloalcano, sua preparação e utilização
US7456171B2 (en) 2002-10-08 2008-11-25 Sanofi-Aventis 1,4-Diazabicyclo[3.2.2]nonanecarboxamide derivatives, preparation and therapeutic use thereof
FR2845388B1 (fr) * 2002-10-08 2004-11-12 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.2]nonanecarboxamides, leur preparation et leur application en therapeutique
EP1562945B1 (de) * 2002-11-11 2006-11-15 Neurosearch A/S 1,4-dizabicyclo(3,2,2)nonane derivative, verfahren zur ihre herstellung und therapeutical verwendung
US7223753B2 (en) * 2002-11-11 2007-05-29 Neurosearch A/S Diazabicyclic biaryl derivatives
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
ES2462545T3 (es) 2002-12-06 2014-05-23 The Feinstein Institute For Medical Research Un procedimiento para la determinación de un agonista colinérgico selectivo para un receptor alfa7 nicotínico
ATE363484T1 (de) * 2003-09-26 2007-06-15 Astrazeneca Ab Nichtamidnonane
US20070191815A1 (en) 2004-09-13 2007-08-16 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
EP1713487B1 (de) * 2004-02-04 2009-12-02 Neurosearch A/S Diazabicyclische aryl-derivate als cholinerge rezeptor-modulatoren
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
EP1734941A2 (de) 2004-03-25 2006-12-27 The Feinstein Institute for Medical Research Neurale staubinde
JP2007538011A (ja) * 2004-05-07 2007-12-27 メモリー・ファーマシューティカルズ・コーポレイション １ｈ−インダゾール、ベンゾチアゾール、１，２−ベンゾイソキサゾール、１，２−ベンゾイソチアゾール、およびクロモン、ならびにそれらの調製および使用
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
WO2006073484A2 (en) 2004-12-27 2006-07-13 North Shore-Long Island Jewish Research Institute Treating inflammatory disorders by electrical vagus nerve stimulation
DE602006019561D1 (de) 2005-02-16 2011-02-24 Neurosearch As Diazabicyclische arylderivate und ihre verwendung als chinolinergische liganden an nikotin-acetylcholin-rezeptoren
FR2889847B1 (fr) 2005-08-18 2007-10-05 Sanofi Aventis Sa Derives de 5-pyridazinyl-1-azabicyclo[3.2.1]octave, leur preparation en therapeutique.
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
US8173658B2 (en) 2005-12-06 2012-05-08 Neurosearch A/S Diazabicycylic aryl derivatives and their medical use
AU2007213669A1 (en) 2006-02-10 2007-08-16 Neurosearch A/S 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7687523B2 (en) 2006-02-10 2010-03-30 Neurosearch A/S 3-heteroaryl-3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists
EP1984366B1 (de) 2006-02-10 2010-12-15 NeuroSearch A/S 3, 9-diazabizyklus ý3.3. 1¨nonanderivate und deren verwendung als monoamin-neurotransmitter-wiederaufnahmehemmer
MX2008014890A (es) 2006-05-30 2008-12-05 Neurosearch As Nuevos derivados de 1,4-diaza-biciclo[3.2.2]nonil pirimidinilo y su uso medico.
ES2521494T3 (es) 2007-04-02 2014-11-12 Parkinson's Institute Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos
WO2009024515A1 (en) * 2007-08-17 2009-02-26 Neurosearch A/S 1,4-diaza-bicycl0(3.2.2)n0nyl pyrimidinyl derivatives useful as nicotinic acetylcholine- receptor ligands
JP2010536726A (ja) * 2007-08-17 2010-12-02 ノイロサーチ アクティーゼルスカブ ニコチン性アセチルコリン受容体リガンドとして有用な新規１，４−ジアザ−ビシクロ〔３．２．２〕ノニルヘテロアリール誘導体
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
DE102007053771A1 (de) * 2007-11-12 2009-05-14 Merck Patent Gmbh Organische Elektrolumineszenzvorrichtungen
US20100305108A1 (en) * 2007-11-14 2010-12-02 Neurosearch A/S Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use
BRPI0820259A2 (pt) 2007-11-14 2015-06-16 Neurosearch As Derivado de 1,4-diaza-biciclo[3.2.2] nonil pirimidina, composição farmacêutica, uso do derivado de 1,4-diaza-biciclo[3.2.2] nonil pirimidina, e, método de tratamento, prevenção ou alívio de uma doença ou uma desordem ou uma condição de um corpo de animal vivo
WO2009146030A1 (en) 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
CN102215909B (zh) 2008-11-18 2014-09-10 赛博恩特医疗器械公司 优化用于消炎刺激的电极放置的装置和方法
US20120028967A1 (en) * 2009-01-21 2012-02-02 Neurosearch A/S Novel diaza-bicyclononyl-pyrimidinyl derivatives and their medical use
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US8788034B2 (en) 2011-05-09 2014-07-22 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
EP2440284B1 (de) 2009-06-09 2018-09-12 Setpoint Medical Corporation Nervenmanschette mit tasche für einen bleifreien stimulator
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
EP2515996B1 (de) 2009-12-23 2019-09-18 Setpoint Medical Corporation Nervenstimulatoren und systeme zur behandlung von chronischer entzündung
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
TW201311698A (zh) * 2011-08-22 2013-03-16 Targacept Inc 作為神經元菸鹼乙醯膽鹼受體配位體之１，４－二氮雜雙環［３．２．２］壬烷
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
EP3405255B1 (de) 2016-01-20 2025-12-31 Setpoint Medical Corporation Implantierbare mikrostimulatoren und induktive ladesysteme
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
CN108882885A (zh) 2016-01-20 2018-11-23 赛博恩特医疗器械公司 迷走神经刺激的控制
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
EP3668402B1 (de) 2017-08-14 2024-07-31 Setpoint Medical Corporation Vagusnervstimulationsvorscreening-test
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
CA3101966A1 (en) 2018-05-29 2019-12-05 Morningside Venture Investments Limited Drug delivery methods and systems
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
US12343535B2 (en) 2019-04-12 2025-07-01 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
EP4090424A4 (de) 2020-01-13 2024-02-21 The Feinstein Institutes for Medical Research Behandlung von blutung und blutungsstörungen durch hochintensive fokussierte ultraschallstimulation der milz
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
WO2022245878A1 (en) 2021-05-17 2022-11-24 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
EP4466064A4 (de) 2022-01-20 2026-01-14 Setpoint Medical Corp Behandlung von entzündungserkrankungen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994460A (en) * 1989-06-01 1991-02-19 Bristol-Myers Squibb Co. Agents for treatment of brain ischemia
NZ274915A (en) * 1993-12-29 1997-11-24 Pfizer N-(hetero)aryl methyl diazabicycloalkane derivatives
US5478939A (en) * 1994-07-20 1995-12-26 American Cyanamid Company (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives
WO1996030372A1 (en) * 1995-03-24 1996-10-03 Japan Tobacco Inc. Diazabicyclo[3.3.1]nonane derivatives and intermediates thereof, medicinal use of the same, and processes for producing the same
JP2668670B2 (ja) * 1995-03-24 1997-10-27 日本たばこ産業株式会社 ジアザビシクロ［３．３．１］ノナン誘導体、その中間体及びその医薬用途

Also Published As

Publication number Publication date
JP4576052B2 (ja) 2010-11-04
FR2786770A1 (fr) 2000-06-09
AR021534A1 (es) 2002-07-24
EP1135389A1 (de) 2001-09-26
AU1393000A (en) 2000-06-26
DE69911241D1 (de) 2003-10-16
DE69911241T2 (de) 2004-07-01
JP2002531565A (ja) 2002-09-24
FR2786770B1 (fr) 2001-01-19
EP1135389B1 (de) 2003-09-10
US6407095B1 (en) 2002-06-18
WO2000034279A1 (fr) 2000-06-15

Similar Documents

Publication Publication Date Title
DE69911241D1 (de) 1,4-diazabicyclo(3.2.2)nonanderivate, deren herstellung und deren verwendung in heilkunde
ATE261972T1 (de) 2,5-diazabicyclo(2.2.1)heptanderivate, deren herstellung und deren verwendung in heilkunde
DE60023012D1 (de) 3(5)-amino-pyrazolderivate, deren herstellungsverfahren und verwendung als krebshemmende mittel
DE60034683D1 (de) 3(5)-ureido-pyrazolderivate, deren herstellungsverfahren und verwendung als krebshemmende mittel
ATE184708T1 (de) Polysiloxan-polyol makromere, deren herstellung und verwendung
DE59814449D1 (de) Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
ATE302604T1 (de) Thienylazolylalkoxyethanamine, deren herstellung und deren verwendung als medikamente
DE69812710D1 (de) Löslicher magnesiumhalogenidkomplex, herstellung und verwendung
ATE310003T1 (de) Benzodiazepin-derivate, deren herstellung und anwendung
DE69814431D1 (de) 3,3-diarylpropylamine , ihre verwendung und herstellung
ATE248186T1 (de) Antipicornavirale verbindungen, deren herstellung und verwendung
DE69901177D1 (de) Platinkomplex, dessen herstellung und dessen therapeutische verwendung
DE69903464D1 (de) Haftverschlüsse, deren herstellung und sie aufweisenden produkten
DE69008454D1 (de) Nitrolsothiolderivate, ihre Herstellung und Verwendung.
DE60008419D1 (de) Farbstoffpräparate, deren herstellung und deren verwendung
DE59800590D1 (de) Polymere organosiliciumverbindungen, deren herstellung und verwendung
ATE261959T1 (de) Substituierte phenyl-piperazin-derivate, deren herstellung und verwendung
ATE242197T1 (de) 3-amino-3-arylpropan-1-ol-derivate, deren herstellung und verwendung
ATE265454T1 (de) Phenyloxazol-1,4-diazabicyclo(3.2.2)nonanderiva e,ihre herstellung und ihre therapeutische verwendung
DE59409541D1 (de) Bicyclen-derivate, ihre herstellung und verwendung
DE60005690D1 (de) Titanverbindungen, deren herstellung und verwendung
DE69204909D1 (de) Amino-Urazilderivate, deren Herstellung und Verwendung.
DE59802922D1 (de) 3-substituierte tetrahydropyridopyrimidinon-derivate, ihre herstellung und verwendung
DE69312319D1 (de) Tachyquinin antagonisten, ihre herstellung und ihre verwendung in pharmazeutischen formulierungen
DE59807020D1 (de) 1:2-chromkomplexfarbstoffe, deren herstellung und verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties